Journal of Bioequivalence & Bioavailability最新文献_第10页

Optimization and Evaluation of Oleic Acid Based Unsaturated Fatty AcidLiposomes Gel 油酸基不饱和脂肪酸脂质体凝胶的优化与评价

Journal of Bioequivalence & Bioavailability Pub Date : 2017-05-25 DOI: 10.4172/JBB.1000336

N. Kaur, R. Garg

引用次数: 3

Atypical Antipsychotics: Do Their Direct Actions on Adipocytes Contribute to Metabolic Disturbances? 非典型抗精神病药物:它们对脂肪细胞的直接作用是否会导致代谢紊乱?

Journal of Bioequivalence & Bioavailability Pub Date : 2017-05-22 DOI: 10.4172/JBB.1000334

Hugo Er, Ben Jonathan N

引用次数: 1

Extrapyramidal Symptoms in Patients Treated with Antipsychotic Drugs 抗精神病药物治疗患者的锥体外系症状

Journal of Bioequivalence & Bioavailability Pub Date : 2017-05-10 DOI: 10.4172/jbb.1000333

F. Werner

引用次数: 1

Comparison of Pharmacokinetic and Pharmacodynamic Effects of Two Hydrofluoroalkane Formulations of Salmeterol 沙美特罗两种氢氟烷烃制剂的药动学和药效学效果比较

Journal of Bioequivalence & Bioavailability Pub Date : 2017-05-02 DOI: 10.4172/JBB.1000332

Nazma Morde, J. Rebello, B. Brashier, M. Garg, Raghu K. Naidu, A. Birhade, K. Iyer, R. Jadhav

{"title":"Comparison of Pharmacokinetic and Pharmacodynamic Effects of Two Hydrofluoroalkane Formulations of Salmeterol","authors":"Nazma Morde, J. Rebello, B. Brashier, M. Garg, Raghu K. Naidu, A. Birhade, K. Iyer, R. Jadhav","doi":"10.4172/JBB.1000332","DOIUrl":"https://doi.org/10.4172/JBB.1000332","url":null,"abstract":"Introduction: To compare the Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of two Hydrofluoroalkane (HFA) formulations of salmeterol xinafoate (Test HFA formulation, Cipla Ltd., India; Reference HFA formulation, Allen and Hanburys, UK) administered using pressurized metered dose inhalers. Methods: Three separate randomized, crossover, PK studies and one PD study comparing the efficacy and safety of the two HFA formulations of salmeterol xinafoate (25 μg per actuation) in healthy subjects were conducted. The PK assessments of the two formulations were done without charcoal blockade, with charcoal blockade, and with a Volumatic spacer device using a single dose. A PD study was also conducted to evaluate the systemic exposure of the two formulations using three different doses (50 μg, 150 μg and 300 μg). Results: In the PK study without charcoal, the 90% CI for the difference between the two formulations for AUC0-t was within the bioequivalence limits of 80-125%; however, Cmax marginally exceeded the upper bioequivalence limit to 136%. In the PK study with charcoal, the 90% CI for the difference between the two formulations for Cmax was within the bioequivalence limits of 80-125%; however, AUC0-t marginally exceeded the upper bioequivalence limit to 128%. The impact of marginally higher systemic exposure was therefore further evaluated in the PD study. The PD study confirmed there were no greater systemic safety effects of the test formulation on the primary PD endpoints such as heart rate and serum potassium as well as on other safety PD endpoints such as blood glucose and QTc interval. The PK study with spacer demonstrated bioequivalence between the test and reference formulations. Both formulations were safe and well tolerated. Conclusion: The test HFA formulation of salmeterol was therapeutically equivalent to the reference HFA formulation of salmeterol when used with and without a spacer.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"15 1","pages":"405-411"},"PeriodicalIF":0.0,"publicationDate":"2017-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89382247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Systemic and Pulmonary Bioavailability of Fluticasone Propionate HFA pMDI 250 Mcg per Actuation With and Without Spacer Device in Healthy Volunteers 健康志愿者每次驱动250 Mcg丙酸氟替卡松HFA pMDI的全身和肺部生物利用度比较，有无间隔装置

Journal of Bioequivalence & Bioavailability Pub Date : 2017-04-27 DOI: 10.4172/jbb.1000331

M. Garg, Raghu K. Naidu, A. Birhade, K. Iyer, R. Jadhav, J. Rebello, Nazma Morde, B. Brashier

{"title":"Comparison of Systemic and Pulmonary Bioavailability of Fluticasone Propionate HFA pMDI 250 Mcg per Actuation With and Without Spacer Device in Healthy Volunteers","authors":"M. Garg, Raghu K. Naidu, A. Birhade, K. Iyer, R. Jadhav, J. Rebello, Nazma Morde, B. Brashier","doi":"10.4172/jbb.1000331","DOIUrl":"https://doi.org/10.4172/jbb.1000331","url":null,"abstract":"Fluticasone Propionate (FP) is a topically active corticosteroid which shows little or no systemic activity after oral administration and is indicated for the prophylactic management of asthma of all severities. The aim of these studies was to evaluate systemic exposure and pulmonary deposition of two Hydrofluoroalkane (HFA) formulations of fluticasone propionate with and without a spacer device in, healthy volunteers. Study-1 was a, randomized, single dose, laboratory-blinded, 2-sequence, 4-period, crossover replicate design without volumatic spacer in 32 healthy volunteers under fasting conditions. Study-2 was a randomized, single dose, laboratory-blinded, 2-sequence, 2-period, crossover design with volumatic spacer in 28 healthy volunteers under fasting conditions. A washout period of 14 days was included in both the studies. Blood samples were collected up to 36 h post-dose for pharmacokinetic profiling. Safety evaluations included assessment of vital signs, clinical laboratory parameters and monitoring of adverse events. A validated LC-MS/MS method was used to measure the plasma concentrations of fluticasone propionate. The 90% CI of the difference between the test (T) and reference (R) for fluticasone propionate was 97.46-112.34 and 98.55-113.06 for Cmax, and AUC0-t respectively in study-1. The 90% CI of the difference between the test and reference for fluticasone propionate was 88.13-104.88, and 96.21-111.22 for Cmax, and AUC0-t respectively in study-2. The 90% CI (T/R) for fluticasone propionate for both Cmax and AUC0-t was within the bioequivalence limits of 80-125% in both the studies. Hence, it was concluded that test and reference formulations of fluticasone propionate HFA pMDI 250 mcg per actuation are equivalent in the systemic exposure and pulmonary deposition with and without a spacer device.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"26 1","pages":"399-404"},"PeriodicalIF":0.0,"publicationDate":"2017-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75886321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological Evaluation of Ocimum sanctum 麝香的药理评价

Journal of Bioequivalence & Bioavailability Pub Date : 2017-04-24 DOI: 10.4172/JBB.1000330

Bano N, A. A, Tanveer M, Khandaker Gm, Ansari Mt

{"title":"Pharmacological Evaluation of Ocimum sanctum","authors":"Bano N, A. A, Tanveer M, Khandaker Gm, Ansari Mt","doi":"10.4172/JBB.1000330","DOIUrl":"https://doi.org/10.4172/JBB.1000330","url":null,"abstract":"Tulsi is a Sanskrit word that means “matchless one”. Ocimum sanctum is a plant of family Lamiaceae, is commonly known as Holy Basil. Characteristically, the plant imparts a pungent, bitter, hot, light and dry effect. Holy Basil is extensively famous and has been used since centuries in Ayurvedic and Greek medicines owing to its beneficially diverse properties. O. sanctum (Tulsi in Hindi) has a significant place in Hindu culture, being used in an array of traditional medicaments and as a condiment. Online published articles, journals, internet sites, Pubmed, Scopus and Google Scholar were explored for data collection. Since Ayurveda times, various parts such as leaves, roots, seeds and whole plant has been recommended for treatment of a spectrum of diseases including bronchitis, dysentery, malaria, diarrhea, eye ailments, dermatological issues, rheumatoid arthritis, etc. Scientifically, it has been proven that O. sanctum possesses anticancer, anti-diabetic, anti-fertility, antifungal, antimicrobial, cardio protective, analgesic, antispasmodic and adaptogenic, immunomodulatory, antioxidant, hepatoprotective, antiallergic, antipyretic, antiviral, antiulcer, anti-inflammatory, CNS depressant and anti-arthritis activities. Its biologically active constituent is known as Eugenol (1-hydroxy-2-methoxy-4-allylbenzene) which is responsible for the mediation of therapeutic characteristics. This review is an attempt to summarize the botanical, pharmacological, phytochemical, ethno medicinal, and toxicological information. This is an effort to help researchers and clinicians to be aware of the magical properties and the effectiveness of Tulsi.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"67 1","pages":"387-392"},"PeriodicalIF":0.0,"publicationDate":"2017-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83849634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 43

The Hidden Ingredients Affecting Cancer Patients Outcome and the Mathematical Journey to Their Uncover 影响癌症患者预后的隐藏因素及其揭示的数学之旅

Journal of Bioequivalence & Bioavailability Pub Date : 2017-04-20 DOI: 10.4172/jbb.1000329

Siegelmann Danieli N, Siegelmann H

引用次数: 0

The Investigation of the Oxidative Stress-Related Parameters in High Doses Methotrexate-Induced Albino Wistar Rats 大剂量甲氨蝶呤诱导的白化Wistar大鼠氧化应激相关参数的研究

Journal of Bioequivalence & Bioavailability Pub Date : 2017-04-07 DOI: 10.4172/JBB.1000327

S. Saka, O. Aouacheri

{"title":"The Investigation of the Oxidative Stress-Related Parameters in High Doses Methotrexate-Induced Albino Wistar Rats","authors":"S. Saka, O. Aouacheri","doi":"10.4172/JBB.1000327","DOIUrl":"https://doi.org/10.4172/JBB.1000327","url":null,"abstract":"Methotrexate (MTX) is used as a chemotherapeutic agent used to treat many cancer types. Methotrexate was known for its toxic effects involving most of the body organs including liver, kidney, intestines and blood components. The aim of the present study was to investigate the antioxidant status during oxidative stress via biological, biochemical and haematological parameters in rats subjected to oral high-doses of methotrexate. Forty male albino rats were equally divided at random into four groups; the first group was the control and the other three groups were treated per os for 7 days with three different doses (1/10, 2/10 and 3/10 of an LD50) of MTX respectively. The methotrexate-treatment of rats caused critical changes in the biological, biochemical and haematological markers. Mainly, an increase in the organo-somatic indexes (organo-megaly), a decrease in urine output value (nephotoxicity) and also a perturbation in most blood components (haematoxicity) were appeared. In addition, MTX has a prooxidant effect, which was indicated by a decrease of the antioxidant parameters in different studied tissues. In view of these results, a close relationship was shown between the increasing MTX-doses and the oxidative stress intensity, characterized by perturbations in biochemical and haematological markers.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"8 1","pages":"372-376"},"PeriodicalIF":0.0,"publicationDate":"2017-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87314553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 27

Wakaskar RR (2017) Types of Nanocarriers–Formulation Method and Applications. Wakaskar RR(2017)纳米载体的种类-制备方法及应用。

Journal of Bioequivalence & Bioavailability Pub Date : 2017-04-07 DOI: 10.4172/JBB.10000E77

Wakaskar Rr

引用次数: 4

Au/Ag NPS Decorated PANI For Electrochemical and Biomedical Applications Au/Ag NPS修饰聚苯胺的电化学和生物医学应用

Journal of Bioequivalence & Bioavailability Pub Date : 2017-04-07 DOI: 10.4172/JBB.1000328

P. Singh, Rajan Patel, K. Kumari, G. K. Mehrotra

引用次数: 3